Emergent BioSolutions (EBS) committed to working with the FDA and Johnson & Johnson to quickly resolve issues

Emergent BioSolutions (EBS) PT Lowered to $67 at Cowen on FDA News

Cowen analyst Boris Peaker lowered the price target on Emergent BioSolutions (NYSE: EBS) to $67.00 (from $86.00) while maintaining a Market Perform rating.

The analyst commented, "The FDA released Form 483 detailing 9 observations of deficiency from a recent inspection at EBS's Bayview facility. We... More